Shares of Oruka Therapeutics (ORKA) are up 28%, or $4.31, to $19.51 in midday trading after MoonLake Immunotherapeutics (MLTX) reported that sonelokimab’s trial in patients with hidradenitis suppurativa missed some of the endpoints. Oruka is also developing a treatment for hidradenitis suppurativa.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics Secures $180M in Private Placement
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Oruka Therapeutics data hits ‘bull case’ scenario, says Clear Street
- Oruka Therapeutics sells 10.9M shares at $15 in private placement
- Oruka Therapeutics announces interim data from ORKA-001 trial at EADV